Krystal Biotech, Inc. 8-K

What Happened
Krystal Biotech, Inc. (KRYS) filed an 8-K on January 8, 2026 announcing a positive interim clinical update from its KB407 Phase 1 CORAL-1 study. The company reported confirmation of wild‑type CFTR delivery to the lungs of patients with cystic fibrosis. Krystal also hosted a conference call and webcast at 4:30 p.m. ET on January 8, 2026 and made a slide presentation available on the Investors section of its website.

Key Details

• Study/program: KB407 Phase 1 CORAL-1 (cystic fibrosis), interim clinical update disclosed Jan 8, 2026.
• Main finding: Company confirmed delivery of wild‑type CFTR protein to patients' lungs.
• Investor materials: Press release and slide presentation made public and attached as Exhibits 99.1 and 99.2 to the 8-K; slides available at www.krystalbio.com.
• Event: Conference call and webcast held at 4:30 p.m. ET on January 8, 2026 to discuss the data.

Why It Matters
Confirmation of wild‑type CFTR delivery is a key early clinical milestone for KB407 and indicates target engagement in the intended organ (the lungs). For investors, this is a material development in Krystal’s clinical program for cystic fibrosis that could influence assessments of program progress and potential value drivers. The filing provides direct company disclosure and supporting materials for investors to review the interim data and management commentary.